Inter Partes Review

PENDING IPRs

Rituxan® (Rituximab)

• IPR2016-01614
  • Patent Number: 7,820,161
  • Patent Owner: Biogen, inc.
  • Petitioner: Celltrion, Inc.
  • Status: Institution decision pending
  • Petition
    Patent Owner Preliminary Response (None filed)
    Decision on Institution
• IPR2016-01667
  • Patent Number: 7,976,838
  • Patent Owner: Genentech, Inc.
  • Petitioner: Celltrion, Inc.
  • Status:  Institution Denied
  • Petition
    Patent Owner Preliminary Response
    Decision Denying Institution
• IPR2017-01093
  • Patent Number: 8,329,172
  • Patent Owner: Biogen
  • Petitioner: Celltrion
  • Status:  Institution Decision Pending
  • Petition
• IPR2017-01094
  • Patent Number: 8,557,244
  • Patent Owner: Biogen
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01095
  • Patent Number: 9,296,821
  • Patent Owner: Biogen
  • Petitioner: Celltrion
  • Status:  Institution Decision Pending
  • Petition
• IPR2017-01227
  • Patent Number: 7,682,612
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status:  Institution Decision Pending
  • Petition
• IPR2017-01229
  • Patent Number: 8,206,711
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01230
  • Patent Number: 7,682,612
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01115
  • Patent number: 7,820,161
  • Patent Owner: Genentech
  • Petitioner: Pfizer
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01166
  • Patent number: 8,329,172
  • Patent Owner:  Biogen, Inc.
  • Petitioner: Pfizer
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01167
  • Patent number: 8,577,244
  • Patent Owner:  Biogen, Inc.
  • Petitioner: Pfizer
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01168
  • Patent number: 8,821,873
  • Patent Owner: Biogen, Inc.
  • Petitioner: Pfizer
  • Status: Institution Decision Pending
  • Petition

Humira® (adalimumab)

• IPR2016-00408
  • Patent number: 8,889,135
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner Response
    Petitioner Reply
• IPR2016-00409
  • Patent number: 8,889,135
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner Response
    Petitioner Reply
• IPR2016-00172
  • Patent number: 8,889,135
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Coherus BioSciences Inc.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner Response
    Petitioner’s Reply
    Petitioner’s Revised Reply
• IPR2016-00188
  • Patent number: 9,017,680
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Coherus BioSciences Inc.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner Response
    Petitioner’s Reply
    Petitioner’s Revised Reply
• IPR2016-00189
  • Patent number: 9,073,987
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Coherus BioSciences Inc.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner Response
    Petitioner’s Reply
    Petitioner’s Revised Reply
• IPR2017-00823
  • Patent number: 9,085,619
  • Patent Owner: AbbVie Biotechnology, Ltd.
  • Petitioner:  Coherus BioSciences Inc.
  • Status: Institution decision pending
  • Petition
    Replacement Petition
• IPR2017-00822
  • Patent number: 9,085,619
  • Patent Owner: AbbVie Biotechnology, Ltd.
  • Petitioner: Coherus BioSciences, Inc.
  • Status: Institution decision pending
  • Petition
    Replacement Petition
• IPR2017-00826
  • Patent number: 9,085,619
  • Patent Owner: AbbVie Biotechnology, Ltd.
  • Petitioner: Coherus BioSciences, Inc.
  • Status: Institution decision pending
  • Petition
• IPR2017-00827
  • Patent number: 9,085,619
  • Patent Owner: AbbVie Biotechnology, Ltd.
  • Petitioner: Coherus BioSciences, Inc.
  • Status: Institution decision pending
  • Petition
• IPR2017-01008
  • Patent number: 9,085,619
  • Patent Owner: AbbVie Biotechnology, Ltd.
  • Petitioner: Coherus BioSciences, Inc.
  • Status: Institution decision pending
  • Petition
• IPR2017-01009
  • Patent number: 9,085,619
  • Patent Owner: AbbVie Biotechnology, Ltd.
  • Petitioner: Coherus BioSciences, Inc.
  • Status: Institution decision pending
  • Petition

General Biologic Patents

• IPR2016-01608
  • Patent number: 6,716,602
  • Patent Owner:  Genentech
  • Petitioner: bioeq
  • Status: Institution Denied
  • Petition
    Patent Owner Preliminary Response
    Petitioner’ Reply to Patent Owner Preliminary Response
    Decision Denying Institution
• IPR2016-00258
  • Patent number: 9,051,556
  • Patent owner: Shire
  • Petitioner: Green Cross Corp.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Final Written Decision
• IPR2017-01129
  • Patent number: 8,679,487
  • Patent Owner: Immunex Corp.
  • Petitioner:  Sanofi-Aventis, Genzyme, and Regeneron
  • Status:  Institution Decision Pending
  • Petition
• IPR2017-01252
  • Patent number: 6,946,292
  • Patent Owner:  Kyowa Kakko Kirin Co., Ltd.
  • Petitioner: Aragen Bioscience, Inc.
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01254
  • Patent number: 8,067,232
  • Patent Owner: Kyowa Hakko Kirin Co., Ltd.
  • Petitioner: Aragen Bioscience, Inc.
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01262
  • Patent number: 7,425,446
  • Patent Owner: Kyowa Hakko Kirin Co., Ltd.
  • Petition: Aragen Bioscience, Inc.
  • Status: Institution Decision Pending
  • Petition

Cabilly Patents

• IPR2016-01373
  • Patent number: 6,331,415
  • Patent owner:  Genentech
  • Petitioner: Merck Sharp & Dohme Corporation
  • Status: Institution denied
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution

• IPR2016-00710
  • Patent number: 6,331,415
  • Patent owner: Genentech, Inc.
  • Petitioner: Mylan Pharmaceuticals Inc.
  • Status: Trial Instituted
  • Petition
    Patent Owner Preliminary Response – None Filed
    Decision on Institution
    Patent Owner Response
    Petitioner’s Reply
    Termination Decision
• IPR2017-00047
  • Patent number: 6,331,415
  • Patent owner: Genentech, Inc.
  • Petitioner:  Merck Sharp and Dohme
  • Status: Petition Instituted
  • Petition
    Decision on Institution

Neulasta (pegfilgrastim)

• IPR2016-01542
  • Patent number: 8,952,138
  • Patent Owner: Amgen
  • Petitioner: Apotex
  • Status: Instituted
  • Petition
    Patent Owner Preliminary Response
    Institution Decision

Herceptin (trastuzumab)

• IPR2016-01693
  • Patent number: 6,407,213
  • Patent Owner: Genentech
  • Petitioner: Mylan
  • Status: Institution Decision Pending
  • Petition
    Patent Owner Preliminary Response
    Termination Decision
• IPR2016-01694
  • Patent number: 6,407,213
  • Patent Owner: Genentech
  • Petitioner: Mylan
  • Status: Institution Decision Pending
  • Petition
    Patent Owner Preliminary Response
    Termination Decision
• IPR2016-01837
  • Patent number: 7,807,799
  • Patent Owner: Genentech
  • Petitioner: Hospira
  • Status: Instituted
  • Petition
    Decision on Institution
• IPR2017-00739
  • Patent number: 7,892,549
  • Patent Owner: Genentech
  • Petitioner: Hospira
  • Status: Institution Decision Pending
  • Petition
  • Patent Owner Preliminary Response
• IPR2017-00737
  • Patent number: 7,892,549
  • Patent Owner: Genentech
  • Petitioner: Hospira
  • Status: Institution Decision Pending
  • Petition
  • Patent Owner Preliminary Response
• IPR2017-00731
  • Patent number: 7,846,441
  • Patent Owner: Genentech
  • Petitioner: Hospira
  • Status: Institution Decision Pending
  • Petition
  • Patent Owner Preliminary Response
• IPR2017-00805
  • Patent number: 7,371,379
  • Patent Owner: Genentech
  • Petitioner: Hospira
  • Status: Institution Decision Pending
  • Petition
  • Patent Owner Preliminary Response
• IPR2017-00804
  • Patent number: 6,627,196
  • Patent Owner: Genentech
  • Petitioner: Hospira
  • Status: Institution Decision Pending
  • Petition
  • Patent Owner Preliminary Response
• IPR2017-00959
  • Patent number: 8,591,897
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01121
  • Patent number: 7,846,441
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01122
  • Patent number: 7,892,549
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01139
  • Patent number: 6,627,196
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition
• IPR2017-01140
  • Patent number: 7,371,379
  • Patent Owner: Genentech
  • Petitioner: Celltrion
  • Status: Institution Decision Pending
  • Petition

Avastin (bevacizumab)

• IPR2016-01771
  • Patent number: 7,622,115
  • Patent Owner:  Genentech
  • Petitioner: Hospira
  • Status: Instituted
  • Petition
    Decision on Institution

TERMINATED IPRS

Rituximab (Rituxan)

• IPR2015-00417
  • Patent number: 7,976,838
  • Patent owner: Genentech, Inc.
  • Petitioner: Boehringer Ingelheim, Pharmaceuticals, Inc.
  • Status: Terminated after institution following request for adverse judgment by petitioner
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
• IPR2015-00415
  • Patent number: 7,820,161
  • Patent owner: Genentech, Inc.
  • Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
  • Status: Terminated after institution following request for adverse judgment by petitioner
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
• IPR2015-00418
  • Patent number: 8,329,172
  • Patent owner: Biogen, Inc.
  • Petitioner: Boehringer Ingelheim Pharmaceuticals, Inc.
  • Status: Denied institution
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
• IPR2015-01744
  • Patent number: 7,820,161
  • Patent owner: Genentech, Inc.
  • Petitioner: Celltrion
  • Status: Terminated prior to institution following motion to dismiss by petitioner
  • Petition
• IPR2015-01733
  • Patent number: 7,976,838
  • Patent owner: Genentech, Inc.
  • Petitioner: Celltrion
  • Status: Terminated prior to institution following motion to dismiss by petitioner
  • Petition

Humira® (adalimumab)

• IPR2015-01514
  • Patent number: 8,916,157
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Amgen Inc.
  • Status: Institution denied
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
• IPR2015-01517
  • Patent number: 8,916,158
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Amgen Inc.
  • Status: Institution denied
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
• IPR2016- 01018
  • Patent number: 9,114,166
  • Patent owner: AbbVie Biotechnology Ltd.
  • Petitioner: Coherus BioSciences Inc.
  • Status: Institution denied
  • Petition
    Patent Owner Preliminary Response
    Decision Denying Institution

Cabilly Patents

• IPR2016-00383
  • Patent number: 6,331,415
  • Patent owner: Genentech, Inc.
  • Petitioner: Genzyme Corporation
  • Status: Institution denied
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution

• IPR2015-01624
  • Patent number: 6,331,415
  • Patent owner: Genentech, Inc.
  • Petitioner: Sanofi-Aventis U.S. LLC
  • Status: Trial terminated following confidential settlement
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner’s Response
    Termination decision
• IPR2016-00460
  • Patent number: 6,331,415
  • Patent owner: Genentech, Inc.
  • Petitioner: Genzyme Corporation
  • Status: Trial terminated following confidential settlement
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Termination Decision

Enbrel® (etanercept)

• IPR2015-01792
  • Patent number: 8,163,522
  • Patent owner: Hoffman-LaRoche Inc.
  • Petitioner: Coalition for Affordable Drugs V LLC
  • Status: Institution denied
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution

Orencia® (abatacept)

• IPR2015-01537
  • Patent number: 8,476,239
  • Patent owner: Bristol-Myers Squibb Company
  • Petitioner: Momenta Pharmaceuticals, Inc.
  • Status: Patent Validity Upheld in FWD
  • Petition
    Patent Owner Preliminary Response
    Decision on Institution
    Patent Owner’s Response
    Final Written Decision

Tysabri (natalizumab)

• IPR2016-00912
  • Patent number: 8,815,236
  • Patent owner: Biogen MA Inc.
  • Petitioner: Swiss Pharma International AG
  • Status: Institution denied – rehearing request pending
  • Petition
    Patent Owner Preliminary Response
    Decision denying institution

• IPR2016-00915
  • Patent number: 8,349,321
  • Patent owner: Biogen MA Inc.
  • Petitioner: Swiss Pharma International AG
  • Status: Institution denied – rehearing request pending
  • Petition
    Patent Owner Preliminary Response
    Decision denying institution

• IPR2016-00916
  • Patent number: 8,900,577
  • Patent owner: Biogen MA Inc.
  • Petitioner: Swiss Pharma International AG
  • Status: Institution denied – rehearing request pending
  • Petition
    Patent Owner Preliminary Response
    Decision denying institution